DOLPAC TABLETS FOR SMALL DOGS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

OXANTEL (AS OXANTEL EMBONATE), PYRANTEL (EQUIVALENT TO PYRANTEL EMBONATE PH.EUR.), PRAZIQUANTEL

Available from:

Vetoquinol UK Limited

ATC code:

QP52AA51

INN (International Name):

OXANTEL (AS OXANTEL EMBONATE), PYRANTEL (EQUIVALENT TO PYRANTEL EMBONATE PH.EUR.), PRAZIQUANTEL

Pharmaceutical form:

Tablets

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Canine

Therapeutic area:

praziquantel, combinations

Therapeutic indications:

Endoparasiticide

Authorization status:

Authorised

Authorization date:

2008-01-25

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Dolpac Tablets for Small Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Pale yellow to yellow, oblong tablet with breaking line.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For curative treatment of dogs harbouring mixed parasitic infestations
with the following adult stages of nematode and
cestode species:
Nematodes:
_Toxocara canis,_
_Toxascaris leonina,_
_Ancylostoma caninum,_
_Uncinaria stenocephala,_
_Trichuris vulpis._
Cestodes:
_Dipylidium caninum_,
_Taenia spp._
_Echinococcus multilocularis_
_Echinococcus granulosus_
4.3 CONTRAINDICATIONS
See section 4.8.
Each tablet contains:
ACTIVE SUBSTANCES:
Oxantel
40.06 mg (equivalent to 111.8 mg of oxantel embonate)
Pyrantel
9.99
mg (equivalent to 28.8 mg of pyrantel embonate)
Praziquantel
10.00 mg
Excipient to one 190 mg divisible tablet
EXCIPIENTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_5_
_/_
_0_
_1_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_5_
_2_
_6_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Parasite resistance to any particular class of anthelmintic may
develop following frequent, repeated use of an
anthelmintic of that class.
Fleas serve as intermediate hosts for one of the common tapeworms –_
Dipylidium caninum_. Tapeworm infesta